3SBIO Shares Surge Over 5% as SSS68 Injection Receives IND Approval for Three Indications in China

Stock News04-30

3SBIO (01530) saw its shares rise more than 5%. At the time of writing, the stock was up 5.13%, trading at HK$23.36 with a turnover of HK$302 million.

According to the latest announcement on the website of China's Center for Drug Evaluation (CDE), the clinical trial application for the Class 1 new drug SSS68 injection (a long-acting anti-APRIL/BAFF bispecific antibody) submitted by Shenyang 3SBIO has received implied approval. The intended indications include the treatment of primary membranous nephropathy (pMN), lupus nephritis (LN), and immunoglobulin A nephropathy (IgAN).

Notably, SSS68 injection is the first APRIL×BAFF bispecific antibody globally to enter the clinical stage.

It is also worth noting that on April 28, the new drug clinical trial application for SSGJ-706 injection, a Class 1 therapeutic biological product independently developed by 3SBIO, was officially accepted. SSGJ-706 is a next-generation tumor immunotherapy drug entirely independently developed by 3SBIO, classified as a Class 1 new therapeutic biological product. It is one of the few PD-1/IL-15 bifunctional fusion proteins in China to reach the IND application stage, with core innovation addressing long-standing clinical challenges in immune cytokine therapies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1161831897?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 10:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161831897","market":"sg","top_or_hot":-1,"title":"3SBIO Shares Surge Over 5% as SSS68 Injection Receives IND Approval for Three Indications in China","media":"Stock News","content":"<p>3SBIO (01530) saw its shares rise more than 5%. At the time of writing, the stock was up 5.13%, trading at HK$23.36 with a turnover of HK$302 million.</p>\n<p>According to the latest announcement on the website of China's Center for Drug Evaluation (CDE), the clinical trial application for the Class 1 new drug SSS68 injection (a long-acting anti-APRIL/BAFF bispecific antibody) submitted by Shenyang 3SBIO has received implied approval. The intended indications include the treatment of primary membranous nephropathy (pMN), lupus nephritis (LN), and immunoglobulin A nephropathy (IgAN).</p>\n<p>Notably, SSS68 injection is the first APRIL×BAFF bispecific antibody globally to enter the clinical stage.</p>\n<p>It is also worth noting that on April 28, the new drug clinical trial application for SSGJ-706 injection, a Class 1 therapeutic biological product independently developed by 3SBIO, was officially accepted. SSGJ-706 is a next-generation tumor immunotherapy drug entirely independently developed by 3SBIO, classified as a Class 1 new therapeutic biological product. It is one of the few PD-1/IL-15 bifunctional fusion proteins in China to reach the IND application stage, with core innovation addressing long-standing clinical challenges in immune cytokine therapies.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3SBIO Shares Surge Over 5% as SSS68 Injection Receives IND Approval for Three Indications in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3SBIO Shares Surge Over 5% as SSS68 Injection Receives IND Approval for Three Indications in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-30 10:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>3SBIO (01530) saw its shares rise more than 5%. At the time of writing, the stock was up 5.13%, trading at HK$23.36 with a turnover of HK$302 million.</p>\n<p>According to the latest announcement on the website of China's Center for Drug Evaluation (CDE), the clinical trial application for the Class 1 new drug SSS68 injection (a long-acting anti-APRIL/BAFF bispecific antibody) submitted by Shenyang 3SBIO has received implied approval. The intended indications include the treatment of primary membranous nephropathy (pMN), lupus nephritis (LN), and immunoglobulin A nephropathy (IgAN).</p>\n<p>Notably, SSS68 injection is the first APRIL×BAFF bispecific antibody globally to enter the clinical stage.</p>\n<p>It is also worth noting that on April 28, the new drug clinical trial application for SSGJ-706 injection, a Class 1 therapeutic biological product independently developed by 3SBIO, was officially accepted. SSGJ-706 is a next-generation tumor immunotherapy drug entirely independently developed by 3SBIO, classified as a Class 1 new therapeutic biological product. It is one of the few PD-1/IL-15 bifunctional fusion proteins in China to reach the IND application stage, with core innovation addressing long-standing clinical challenges in immune cytokine therapies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1161831897","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161831897","pubTimestamp":1777516836,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"3SBIO (01530) saw its shares rise more than 5%. At the time of writing, the stock was up 5.13%, trading at HK$23.36 with a turnover of HK$302 million. According to the latest announcement on the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","VXUS":"国际股票ETF-Vanguard","BK1593":"医美概念股","IND":"Xtrackers Nifty 500 India ETF","01530":"三生制药","BK1583":"高瓴概念","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币"},"translate_title":"SSS68注射液在中国获得三种适应症IND批准，三生制药股价飙升逾5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IND":1,"01530":1,"VXUS":1},"content_text":"3SBIO (01530) saw its shares rise more than 5%. At the time of writing, the stock was up 5.13%, trading at HK$23.36 with a turnover of HK$302 million.\nAccording to the latest announcement on the website of China's Center for Drug Evaluation (CDE), the clinical trial application for the Class 1 new drug SSS68 injection (a long-acting anti-APRIL/BAFF bispecific antibody) submitted by Shenyang 3SBIO has received implied approval. The intended indications include the treatment of primary membranous nephropathy (pMN), lupus nephritis (LN), and immunoglobulin A nephropathy (IgAN).\nNotably, SSS68 injection is the first APRIL×BAFF bispecific antibody globally to enter the clinical stage.\nIt is also worth noting that on April 28, the new drug clinical trial application for SSGJ-706 injection, a Class 1 therapeutic biological product independently developed by 3SBIO, was officially accepted. SSGJ-706 is a next-generation tumor immunotherapy drug entirely independently developed by 3SBIO, classified as a Class 1 new therapeutic biological product. It is one of the few PD-1/IL-15 bifunctional fusion proteins in China to reach the IND application stage, with core innovation addressing long-standing clinical challenges in immune cytokine therapies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1161831897","isCrawlerRequest":true}